Another study determined that the combination of celecoxib and trametinib increased total NF-κB protein expression while simultaneously inhibiting NF-κB activation, leading to an antiproliferative and proapoptotic therapeutic effect in melanoma treatment [52]. The gene discussed is NFKB1; the disease is melanoma.